RU2455994C2 - Пиримидиновые производные - Google Patents
Пиримидиновые производные Download PDFInfo
- Publication number
- RU2455994C2 RU2455994C2 RU2009141982/04A RU2009141982A RU2455994C2 RU 2455994 C2 RU2455994 C2 RU 2455994C2 RU 2009141982/04 A RU2009141982/04 A RU 2009141982/04A RU 2009141982 A RU2009141982 A RU 2009141982A RU 2455994 C2 RU2455994 C2 RU 2455994C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- indol
- pyrimidin
- ylamino
- phenyl
- Prior art date
Links
- 0 Cc1cc(c(*)c(cc2)Nc3nc(Nc4cccc(*CCNC)c4)ncc3)c2[n]1 Chemical compound Cc1cc(c(*)c(cc2)Nc3nc(Nc4cccc(*CCNC)c4)ncc3)c2[n]1 0.000 description 4
- KVZWYIQMJOZZNJ-UHFFFAOYSA-N CCC(C(C)=C1)c(cc2)c1c(F)c2Nc1ccnc(Nc2ccc(CC(OC)=O)cc2)n1 Chemical compound CCC(C(C)=C1)c(cc2)c1c(F)c2Nc1ccnc(Nc2ccc(CC(OC)=O)cc2)n1 KVZWYIQMJOZZNJ-UHFFFAOYSA-N 0.000 description 1
- PJHKJALVCXSIPC-UHFFFAOYSA-N COc(c(OC)c1)ccc1Nc(nc1Nc(cccc2)c2C(N)=O)ncc1C#N Chemical compound COc(c(OC)c1)ccc1Nc(nc1Nc(cccc2)c2C(N)=O)ncc1C#N PJHKJALVCXSIPC-UHFFFAOYSA-N 0.000 description 1
- GMQPIGJXSZAXSJ-UHFFFAOYSA-N CS(N1CCCC1)(=O)=O Chemical compound CS(N1CCCC1)(=O)=O GMQPIGJXSZAXSJ-UHFFFAOYSA-N 0.000 description 1
- HLRHFJGCNSCEQO-UHFFFAOYSA-N Cc([nH]c1ccc2Nc3ccnc(Nc4cccc(OS(C)(=O)=O)c4)n3)cc1c2F Chemical compound Cc([nH]c1ccc2Nc3ccnc(Nc4cccc(OS(C)(=O)=O)c4)n3)cc1c2F HLRHFJGCNSCEQO-UHFFFAOYSA-N 0.000 description 1
- HTQHYYMBTXZIKS-UHFFFAOYSA-N Cc([nH]c1ccc2Oc3ccnc(Nc(cc4)cnc4OC)n3)cc1c2F Chemical compound Cc([nH]c1ccc2Oc3ccnc(Nc(cc4)cnc4OC)n3)cc1c2F HTQHYYMBTXZIKS-UHFFFAOYSA-N 0.000 description 1
- RGOFWPASXIASRQ-UHFFFAOYSA-N Cc([nH]c1ccc2Oc3nc(Nc4cccc(CC(NCCN5CCOCC5)=O)c4)ncc3)cc1c2F Chemical compound Cc([nH]c1ccc2Oc3nc(Nc4cccc(CC(NCCN5CCOCC5)=O)c4)ncc3)cc1c2F RGOFWPASXIASRQ-UHFFFAOYSA-N 0.000 description 1
- GHSOXRLOYVBTCZ-UHFFFAOYSA-N Cc1cc(c(F)c(cc2)Nc3ccnc(Nc(cn4)ccc4OC)n3)c2[nH]1 Chemical compound Cc1cc(c(F)c(cc2)Nc3ccnc(Nc(cn4)ccc4OC)n3)c2[nH]1 GHSOXRLOYVBTCZ-UHFFFAOYSA-N 0.000 description 1
- MNNRQGVXYHRHOL-UHFFFAOYSA-N Cc1cc(c(F)c(cc2)Nc3ccnc(Nc4cc(OCCN5CCCC5)ccc4)n3)c2[nH]1 Chemical compound Cc1cc(c(F)c(cc2)Nc3ccnc(Nc4cc(OCCN5CCCC5)ccc4)n3)c2[nH]1 MNNRQGVXYHRHOL-UHFFFAOYSA-N 0.000 description 1
- BACKVALOZUOQCN-UHFFFAOYSA-N Cc1cc(c(F)c(cc2)Nc3nc(Nc4cccc(OC5CNCCC5)c4)ncc3)c2[nH]1 Chemical compound Cc1cc(c(F)c(cc2)Nc3nc(Nc4cccc(OC5CNCCC5)c4)ncc3)c2[nH]1 BACKVALOZUOQCN-UHFFFAOYSA-N 0.000 description 1
- CGPBYTHLFCKJHA-UHFFFAOYSA-N Cc1cc(cc(cc2)Nc3nc(NCCN4CCOCC4)ncc3)c2[nH]1 Chemical compound Cc1cc(cc(cc2)Nc3nc(NCCN4CCOCC4)ncc3)c2[nH]1 CGPBYTHLFCKJHA-UHFFFAOYSA-N 0.000 description 1
- HPUAHIWHACKSIR-UHFFFAOYSA-N Cc1cc(cc(cc2)Nc3nc(Nc(cc4Cl)ccc4F)ncc3)c2[nH]1 Chemical compound Cc1cc(cc(cc2)Nc3nc(Nc(cc4Cl)ccc4F)ncc3)c2[nH]1 HPUAHIWHACKSIR-UHFFFAOYSA-N 0.000 description 1
- ZPYJTBCBUVBCKG-UHFFFAOYSA-N Cc1cc(cc(cc2)Nc3nc(Nc4cc(C(NCCN(C)C)=O)ccc4)ncc3)c2[nH]1 Chemical compound Cc1cc(cc(cc2)Nc3nc(Nc4cc(C(NCCN(C)C)=O)ccc4)ncc3)c2[nH]1 ZPYJTBCBUVBCKG-UHFFFAOYSA-N 0.000 description 1
- NODQEOAIZUTCAM-UHFFFAOYSA-N Cc1cc(cc(cc2)Nc3nc(Nc4cc(OCCCN(C)C)ccc4)ncc3)c2[nH]1 Chemical compound Cc1cc(cc(cc2)Nc3nc(Nc4cc(OCCCN(C)C)ccc4)ncc3)c2[nH]1 NODQEOAIZUTCAM-UHFFFAOYSA-N 0.000 description 1
- LSNYNYZOYKHQOG-UHFFFAOYSA-N Cc1cc(cc(cc2)Nc3nc(Nc4cc(OCCO)ccc4)ncc3)c2[nH]1 Chemical compound Cc1cc(cc(cc2)Nc3nc(Nc4cc(OCCO)ccc4)ncc3)c2[nH]1 LSNYNYZOYKHQOG-UHFFFAOYSA-N 0.000 description 1
- SRHOFLLNRAEYQA-UHFFFAOYSA-N Cc1cc2cc(Nc3ccnc(Nc(cc4)ccc4NS(C(F)(F)F)(=O)=O)n3)ccc2[nH]1 Chemical compound Cc1cc2cc(Nc3ccnc(Nc(cc4)ccc4NS(C(F)(F)F)(=O)=O)n3)ccc2[nH]1 SRHOFLLNRAEYQA-UHFFFAOYSA-N 0.000 description 1
- JGPWPSZDUNCWCK-UHFFFAOYSA-N Cc1cc2cc(Nc3ccnc(Nc4cc(C(NC)=O)ccc4)n3)ccc2[nH]1 Chemical compound Cc1cc2cc(Nc3ccnc(Nc4cc(C(NC)=O)ccc4)n3)ccc2[nH]1 JGPWPSZDUNCWCK-UHFFFAOYSA-N 0.000 description 1
- RAFYOROBWBKYGV-UHFFFAOYSA-N Cc1cc2cc(Nc3nc(Nc4cc(CN5CCC(CO)CC5)ccc4)ncc3)ccc2[nH]1 Chemical compound Cc1cc2cc(Nc3nc(Nc4cc(CN5CCC(CO)CC5)ccc4)ncc3)ccc2[nH]1 RAFYOROBWBKYGV-UHFFFAOYSA-N 0.000 description 1
- KNVIGJNYPRGGFL-UHFFFAOYSA-N Cc1cc2cc(Nc3nc(Nc4cc(OCC5CCNCC5)ccc4)ncc3)ccc2[nH]1 Chemical compound Cc1cc2cc(Nc3nc(Nc4cc(OCC5CCNCC5)ccc4)ncc3)ccc2[nH]1 KNVIGJNYPRGGFL-UHFFFAOYSA-N 0.000 description 1
- QMHMOLFIFQJWND-UHFFFAOYSA-N Cc1cc2cc(Nc3nc(Nc4cccc(C(NCCO)=O)c4)ncc3)ccc2[nH]1 Chemical compound Cc1cc2cc(Nc3nc(Nc4cccc(C(NCCO)=O)c4)ncc3)ccc2[nH]1 QMHMOLFIFQJWND-UHFFFAOYSA-N 0.000 description 1
- CORUQLRWPYWRNS-UHFFFAOYSA-N Cc1cc2cc(OCc3nc(Nc4cc(OCCCN5CCOCC5)ccc4)ncc3C#N)ccc2[nH]1 Chemical compound Cc1cc2cc(OCc3nc(Nc4cc(OCCCN5CCOCC5)ccc4)ncc3C#N)ccc2[nH]1 CORUQLRWPYWRNS-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N Clc1nc(Cl)ncc1 Chemical compound Clc1nc(Cl)ncc1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- RRHQIRUDDBKIEN-UHFFFAOYSA-N Clc1nccc(Nc(cc2)cc3c2[nH]cn3)n1 Chemical compound Clc1nccc(Nc(cc2)cc3c2[nH]cn3)n1 RRHQIRUDDBKIEN-UHFFFAOYSA-N 0.000 description 1
- BHUSBPXIWBLDIU-UHFFFAOYSA-N N#Cc1cccc(Nc2nccc(Nc3ccc4[nH]cnc4c3)n2)c1 Chemical compound N#Cc1cccc(Nc2nccc(Nc3ccc4[nH]cnc4c3)n2)c1 BHUSBPXIWBLDIU-UHFFFAOYSA-N 0.000 description 1
- WFRXSXUDWCVSPI-UHFFFAOYSA-N Nc1ccc2[nH]cnc2c1 Chemical compound Nc1ccc2[nH]cnc2c1 WFRXSXUDWCVSPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91192107P | 2007-04-16 | 2007-04-16 | |
| US60/911,921 | 2007-04-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009141982A RU2009141982A (ru) | 2011-05-27 |
| RU2455994C2 true RU2455994C2 (ru) | 2012-07-20 |
Family
ID=39854302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009141982/04A RU2455994C2 (ru) | 2007-04-16 | 2008-04-15 | Пиримидиновые производные |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8349859B2 (enExample) |
| EP (1) | EP2154967B9 (enExample) |
| JP (1) | JP5635398B2 (enExample) |
| KR (1) | KR101424847B1 (enExample) |
| BR (1) | BRPI0809715A2 (enExample) |
| CA (1) | CA2684470C (enExample) |
| DK (1) | DK2154967T5 (enExample) |
| ES (1) | ES2465673T3 (enExample) |
| HR (1) | HRP20140377T2 (enExample) |
| MX (1) | MX2009011199A (enExample) |
| NZ (1) | NZ580671A (enExample) |
| PL (1) | PL2154967T3 (enExample) |
| PT (1) | PT2154967E (enExample) |
| RU (1) | RU2455994C2 (enExample) |
| SI (1) | SI2154967T1 (enExample) |
| TW (1) | TWI484960B (enExample) |
| WO (1) | WO2008128231A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2701188C2 (ru) * | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药（上海）有限公司 | 一种化合物及其晶体 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| EP2395001A1 (en) | 2010-05-21 | 2011-12-14 | Chemilia AB | Novel pyrimidine derivatives |
| EP2433636A1 (en) * | 2010-09-27 | 2012-03-28 | Medizinische Universität Wien | Treatment of Malignant Diseases |
| US8785467B2 (en) | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| BR112015010109A2 (pt) * | 2012-11-05 | 2017-07-11 | Nant Holdings Ip Llc | derivados de indol-5-ol substituídos e suas aplicações terapêuticas |
| WO2014145403A1 (en) * | 2013-03-15 | 2014-09-18 | Nantbio, Inc. | Substituted indol-5-ol derivatives and their therapeutic applications |
| CN105601573B (zh) * | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| US10981899B2 (en) | 2016-04-28 | 2021-04-20 | Cornell University | Inhibitors of soluble adenylyl cyclase |
| WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
| CN111004221B (zh) * | 2019-12-13 | 2021-02-02 | 长治学院 | 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途 |
| US20240166635A1 (en) * | 2020-11-27 | 2024-05-23 | Anrui Biomedical Technology (Guangzhou) Co.,Ltd. | Aminoheteroaryl kinase inhibitors |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| WO2002102783A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20030149041A1 (en) * | 1999-12-28 | 2003-08-07 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| US6723726B1 (en) * | 1996-07-13 | 2004-04-20 | Smithkline Beecham Corporation | Protein tyrosine kinase inhibitors |
| RU2005108999A (ru) * | 2002-08-30 | 2005-08-27 | Эйсай Ко., Лтд. (JP) | Азотсодержащие ароматические производные |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| PL199802B1 (pl) | 1999-02-10 | 2008-10-31 | Astrazeneca Ab | Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| KR100847169B1 (ko) * | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
| WO2002070477A1 (en) * | 2001-03-01 | 2002-09-12 | Ono Pharmaceutical Co., Ltd. | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003220970A1 (en) | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| WO2003106416A2 (en) | 2002-06-17 | 2003-12-24 | Smithkline Beecham Corporation | Chemical process |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| JP2006503081A (ja) | 2002-10-10 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化学化合物 |
| CN1717396A (zh) | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途 |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| US20050267182A1 (en) * | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| US7718697B2 (en) | 2003-12-17 | 2010-05-18 | Alcon, Inc. | Method for treating glaucoma comprising administering α-lipoic acid |
| MXPA06007242A (es) | 2003-12-23 | 2006-08-18 | Pfizer | Nuevos derivados de quinolina. |
| DE102004044556A1 (de) * | 2004-09-15 | 2006-03-30 | Bayer Healthcare Ag | Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren |
| TW200628463A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| WO2006060194A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2604551A1 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
| WO2006138304A2 (en) | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
| WO2007035309A1 (en) * | 2005-09-15 | 2007-03-29 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
-
2008
- 2008-04-15 HR HRP20140377AT patent/HRP20140377T2/hr unknown
- 2008-04-15 JP JP2010504191A patent/JP5635398B2/ja not_active Expired - Fee Related
- 2008-04-15 ES ES08745881.6T patent/ES2465673T3/es active Active
- 2008-04-15 EP EP08745881.6A patent/EP2154967B9/en active Active
- 2008-04-15 WO PCT/US2008/060366 patent/WO2008128231A1/en not_active Ceased
- 2008-04-15 TW TW097113595A patent/TWI484960B/zh not_active IP Right Cessation
- 2008-04-15 CA CA2684470A patent/CA2684470C/en active Active
- 2008-04-15 SI SI200831203T patent/SI2154967T1/sl unknown
- 2008-04-15 PL PL08745881T patent/PL2154967T3/pl unknown
- 2008-04-15 NZ NZ580671A patent/NZ580671A/xx not_active IP Right Cessation
- 2008-04-15 BR BRPI0809715-1A patent/BRPI0809715A2/pt not_active Application Discontinuation
- 2008-04-15 DK DK08745881.6T patent/DK2154967T5/en active
- 2008-04-15 PT PT87458816T patent/PT2154967E/pt unknown
- 2008-04-15 RU RU2009141982/04A patent/RU2455994C2/ru active
- 2008-04-15 KR KR1020097023882A patent/KR101424847B1/ko not_active Expired - Fee Related
- 2008-04-15 MX MX2009011199A patent/MX2009011199A/es active IP Right Grant
- 2008-04-16 US US12/103,876 patent/US8349859B2/en not_active Expired - Fee Related
-
2012
- 2012-11-08 US US13/672,078 patent/US8901143B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723726B1 (en) * | 1996-07-13 | 2004-04-20 | Smithkline Beecham Corporation | Protein tyrosine kinase inhibitors |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US20030149041A1 (en) * | 1999-12-28 | 2003-08-07 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| WO2002102783A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| RU2005108999A (ru) * | 2002-08-30 | 2005-08-27 | Эйсай Ко., Лтд. (JP) | Азотсодержащие ароматические производные |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2701188C2 (ru) * | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008128231A1 (en) | 2008-10-23 |
| EP2154967B9 (en) | 2014-07-23 |
| EP2154967A4 (en) | 2010-05-19 |
| JP5635398B2 (ja) | 2014-12-03 |
| DK2154967T3 (da) | 2014-04-07 |
| CA2684470A1 (en) | 2008-10-23 |
| HRP20140377T1 (en) | 2014-05-23 |
| EP2154967A1 (en) | 2010-02-24 |
| AU2008240084A1 (en) | 2008-10-23 |
| US20080255172A1 (en) | 2008-10-16 |
| MX2009011199A (es) | 2010-03-17 |
| JP2010524952A (ja) | 2010-07-22 |
| US8901143B2 (en) | 2014-12-02 |
| TWI484960B (zh) | 2015-05-21 |
| EP2154967B1 (en) | 2014-03-05 |
| CA2684470C (en) | 2016-02-09 |
| ES2465673T9 (es) | 2014-11-14 |
| RU2009141982A (ru) | 2011-05-27 |
| HRP20140377T2 (hr) | 2015-01-16 |
| BRPI0809715A2 (pt) | 2019-11-05 |
| PL2154967T3 (pl) | 2014-08-29 |
| TW200848049A (en) | 2008-12-16 |
| DK2154967T5 (en) | 2014-11-17 |
| PT2154967E (pt) | 2014-06-05 |
| US20130065890A1 (en) | 2013-03-14 |
| ES2465673T3 (es) | 2014-06-06 |
| NZ580671A (en) | 2012-03-30 |
| US8349859B2 (en) | 2013-01-08 |
| KR101424847B1 (ko) | 2016-07-08 |
| KR20100016592A (ko) | 2010-02-12 |
| SI2154967T1 (sl) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2455994C2 (ru) | Пиримидиновые производные | |
| CN101723936B (zh) | 激酶抑制剂及其在药学中的用途 | |
| TWI458724B (zh) | 喹唑啉衍生物 | |
| RU2505534C2 (ru) | Производные хиназолина, ингибирующие активность egfr | |
| CN105541836A (zh) | 激酶抑制剂的前药形式及其在治疗中的用途 | |
| KR20140117684A (ko) | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 | |
| CN101289444B (zh) | 一种嘧啶衍生物及其医药用途 | |
| US8501957B2 (en) | Benzimidazole compounds and their use as anticancer agents | |
| AU2008240084B2 (en) | Pyrimidine derivatives | |
| US7737157B2 (en) | Pyrimidine compounds | |
| CN112625025B (zh) | 吡啶基取代的喹啉类衍生物及其制备方法和用途 |